## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($16.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Kenvue and J&J must register in Texas or face business ban, judge rules**
- Source: Investing.com Canada | 20251208T181446 | Neutral | Relevance: 98%
-  A Texas judge has ordered Kenvue Inc. and its former parent Johnson & Johnson to register with the Texas Secretary of State or risk being barred from doing business in the state. This ruling stems from a lawsuit filed by Texas Attorney General Ken Paxton, who also has a separate lawsuit alleging the companies hid risks of autism and other disorders in children whose mothers took Tylenol during pregnancy. The judge's temporary order requires compliance with Texas business registration laws, with a follow-up hearing scheduled for December 15th to consider further restrictions.

**2. Brown Advisory Inc. Cuts Position in Kenvue Inc. $KVUE**
- Source: MarketBeat | 20251207T090143 | Neutral | Relevance: 98%
-  Brown Advisory Inc. reduced its stake in Kenvue Inc. by 8.2% in the second quarter, selling 114,055 shares while still owning 1,283,006 shares valued at $26.85 million. Despite this, other major institutional investors like Amundi and Invesco increased their positions, with hedge funds and institutions collectively holding approximately 97.64% of Kenvue's stock. Kenvue (NYSE:KVUE) currently trades around $16.92, offers a 4.9% dividend yield with a 110.7% payout ratio, and has a consensus "Hold" rating from analysts with an average price target of $20.23.

**3. Kenvue Inc. $KVUE Position Raised by Ossiam**
- Source: MarketBeat | 20251208T115129 | Neutral | Relevance: 98%
-  Ossiam significantly increased its stake in Kenvue Inc. (NYSE:KVUE) by 679.3% in the second quarter, bringing its total holdings to 1,332,897 shares valued at approximately $27.9 million. This move is part of broader institutional investment trends, with various other firms also adjusting their positions in Kenvue, which currently holds a consensus "Hold" rating from analysts with an average target price of $20.23. The company recently reported Q3 earnings per share of $0.28, beating estimates, and announced a quarterly dividend reflecting a 4.9% yield.

**4. Kenvue Inc. $KVUE Shares Bought by Burgundy Asset Management Ltd.**
- Source: MarketBeat | 20251207T100814 | Somewhat-Bullish | Relevance: 98%
-  Burgundy Asset Management Ltd. significantly increased its stake in Kenvue Inc. ($KVUE) by 9.0% in the second quarter, now owning 7,148,796 shares valued at $149.62 million. Several other institutional investors also adjusted their positions, with 97.64% of the stock currently held by hedge funds and institutional investors. Analysts have issued mixed ratings, resulting in an average "Hold" consensus and a price target of $20.23, while Kenvue recently declared a quarterly dividend of $0.2075.

**5. The Motley Fool: Kimberly-Clark is growing**
- Source: Dallas News | 20251207T110314 | Bullish | Relevance: 98%
-  Kimberly-Clark is acquiring Kenvue for approximately $48.7 billion, creating a health and wellness giant projected to generate $32 billion in revenue and boasting ten brands with over $1 billion in annual sales each. The deal is expected to yield a net benefit of $2.1 billion within four years and strengthen the combined company's financial position, despite initial debt; however, potential legal issues remain a risk. The article also provides general investment advice, including an explanation of "earnings season" and Philip A. Fisher's 15 points for evaluating common stocks.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Barclays | $18 | $17 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Barclays | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Long-term trend broken: trading 16.8% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.86 indicates undervaluation relative to growth. Forward P/E 15.4x stretched relative to 7% growth. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $32.7B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.86 |
| Forward P/E | 15.4 |
| Current P/E | 16.5 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.9% (minimal 5-day change). Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Below SMA200 (0.83x), long-term trend not supportive. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.86% (CS: 50) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.00 | Bearish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 0.832x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $17.02
- **Stop Loss:** $16.14 (5.2% risk)
- **Target:** $17.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $9,667.36
- **Portfolio %:** 9.67%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*